Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase Ia/Ib Study of the Combination of the FGFR Inhibitor Pemigatinib and the EGFR Inhibitor Afatinib in Advanced Refractory Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06302621
• Other study ID #: 21-725
• Status: Recruiting
• Phase: Phase 1
• Start date: July 1, 2024
• Est. completion date: December 1, 2025

Study information

• Verified date: April 2024
• Source: Massachusetts General Hospital
• Contact: Andreas Varkaris, MD
• Phone: 617-724-4000
• Email: AVARKARIS[@]MGH.HARVARD.EDU
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable side effects. This research study involves the study drugs Afatinib and Pemigatinib.

Description:

This is an open-label phase Ia/Ib study to evaluate safety, tolerability and preliminary efficacy of the combination of pemigatinib and afatinib in patients with FGFR-altered refractory advanced solid tumors. This study includes 2 parts: phase 1a dose escalation and phase 1b dose expansion. - In the phase 1a dose escalation study patients with FGFR-altered refractory advanced refractory solid tumors will be enrolled. - In the phase Ib dose expansion study, patients with FGFR-altered cholangiocarcinoma will be recruited into 2 cohorts: FGFR inhibitor-naïve cholangiocarcinoma and FGFR-inhibitor-pretreated and resistant cholangiocarcinoma. The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. This research study involves the study drugs Afatinib and Pemigatinib. Participants will receive study treatment for as long there is benefit and no unacceptable side effects. Participants will be followed for up to 1 year. It is expected that up to 70 people will take part in this research study. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved afatinib for this specific disease but it has been approved for other uses. The U.S. Food and Drug Administration (FDA) has approved pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion. The FDA has not approved the combination of afatinib and pemigatinib as a treatment for any disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: December 1, 2025
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

All Patients

• Unresectable or metastatic, histologically confirmed advanced solid tumor, where standard curative or palliative measures are no longer effective or are not considered appropriate or safe in the opinion of the investigator.
• FGFR1-3 fusion, rearrangement, activating mutation, or FGFR2 extracellular domain in-frame deletions on tumor profiling in tumor tissue as determined by testing routinely performed at a Clinical Laboratory Improvement Amendments (CLIA) or other similarly certified laboratory. If the FGFR alteration is present on circulating tumor DNA (ctDNA) analysis alone, the patient may be eligible with principal investigator approval. Additional mutations may be considered with principal investigator approval.
• Eastern Cooperative Oncology Group (ECOG) 0-1.
• At least 18 years of age.
• Ability to swallow tablets.
• Life expectancy >/=3 months
• Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation.
• Patients with cholangiocarcinoma must have adequate biliary drainage (per investigator's discretion), with no evidence of ongoing infection.
• Willingness of men and women of reproductive potential to observe conventional and effective birth control for the duration of treatment and for 3 months following the last dose of study treatment.
• Measurable or non-measurable disease as determined by RECIST 1.1.
• Adequate organ function defined as:
• ALT or AST = 3 × the ULN in the absence of liver metastases, OR = 5 × ULN with documented liver metastases
• Total bilirubin = 2.0 × ULN in the absence of Gilbert's Disease, OR = 3 × ULN with Gilbert's Disease provided direct bilirubin is = ULN
• Serum Creatinine = 1.5 × ULN OR calculated creatinine clearance = 60ml/min
• Hemoglobin = 9 g/dL (= 90 g/L)
• Absolute Neutrophil Count = 1.5 x 109/L
• Platelets = 75 x 109/L
• INR or PT, aPTT or PTT = 1.5 × ULN unless participant is receiving anticoagulant therapy
• NOTE: Transfusions to increase a patient's hemoglobin level or initiation of erythropoietin or G-CSF therapy to meet enrollment criteria are not allowed in the 14 days preceding the first dose of study drug. If a patient receives transfusions, erythropoietin, or G-CSF therapy = 14 days prior to the first dose, the hematologic criteria listed above must be met following the 14-day window and prior to the first dose of study therapy Dose expansion cohort 1: Patients should fulfill the eligibility criteria above for all

patients in addition to the following:

• Histologically or cytologically confirmed diagnosis of advanced or metastatic cholangiocarcinoma
• No prior treatment with a selective FGFR inhibitor treatment
• FGFR2 fusion, in-frame rearrangement, or extracellular domain in-frame deletion on tumor profiling in tumor tissue as determined by testing routinely performed on tumor biopsy at a CLIA or other similarly certified laboratory. If the FGFR alteration is present on ctDNA analysis alone, the patient may be eligible with principal investigator approval.
• An archived tumor tissue sample is available in patients not undergoing fresh tumor biopsy. Patients who do not have adequate archival tumor tissue available are required to undergo a fresh tumor biopsy. If a fresh biopsy cannot be safely performed, the patient may be eligible with principal investigator approval. Dose expansion cohort 2: Patients should fulfill the eligibility criteria above for all

patients in addition to the following:

• Histologically or cytologically confirmed diagnosis of advanced or metastatic cholangiocarcinoma
• Prior FGFR inhibitor treatment at any time prior to treatment start is required
• FGFR2 fusion, in-frame rearrangement, or extracellular domain in-frame deletion for which they derived clinical benefit (objective response of any duration or stable disease for at least 6 months) from prior FGFR inhibitor therapy, as determined by testing routinely performed on tumor biopsy at a CLIA or other similarly certified laboratory. If the FGFR alteration is present on ctDNA analysis alone, the patient may be eligible with principal investigator approval
• An archived tumor tissue sample after progression on or intolerance of prior FGFR inhibitor available in patients not undergoing fresh tumor biopsy. Patients who do not have adequate archival tumor tissue available are required to undergo a fresh tumor biopsy. If a fresh biopsy cannot be safely performed, the patient may be eligible with principal investigator approval.

Exclusion Criteria:

• Known hypersensitivity to afatinib or pemigatinib or excipients of pemigatinib
• For patients treated with a prior FGFR inhibitor, those with known activating mutation(s) in the FGFR2 kinase domain on ctDNA or biopsy analysis within 8 weeks of start of study drugs; activating mutations in the FGFR2 kinase domain seen on ctDNA or biopsy analysis prior to the 8-week timepoint may be allowed after discussion with the study PI.
• Systemic or liver-directed anticancer therapy within 2 weeks; or anticancer monoclonal antibody within 4 weeks prior to planned start of pemigatinib and afatinib.
• Patient has adverse events from prior therapy that have not resolved to = grade 1; exceptions for non-clinically meaningful adverse events (AEs) can be made with input from the principal investigator.
• Major surgery within 4 weeks prior to planned start of pemigatinib and afatinib (tumor biopsy, biliary stent or catheter placement, and feeding tube placement are not considered major surgical procedures).
• Received prior palliative non-CNS radiation within 2 weeks or extended-field radiation administered within 4 weeks of first dose of study drug. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. Fibrotic pulmonary disease from prior radiotherapy is permissible with approval of the study PI.
• Known pre-existing interstitial lung disease
• Current hypovitaminosis D requiring supraphysiologic (eg 50,000 IU/weekly) to replenish the deficiency. Vitamin D supplements are allowed.
• History and/or current evidence of clinically significant ectopic mineralization/calcification or non-tumor related alteration of calcium-phosphorus homeostasis.
• History and/or current evidence of clinically significant corneal or retinal disorder confirmed by ophthalmological examination
• Child-Pugh B and C cirrhosis
• Chronic nausea, vomiting, or diarrhea considered to be clinically significant in the opinion of the investigator. This includes significant or recent gastrointestinal disorders with diarrhea as a major symptom
• Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug.
• Patients with a history of another primary malignancy that is currently clinically significant, and has potential for metastases or currently requires active intervention (except for gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LH-RH) agonists in prostate cancer or hormonal therapy in breast cancer
• Have history of hepatic encephalopathy of any grade
• Patients with ascites requiring serial paracenteses
• Active central nervous system (CNS) metastases are not eligible. Patients with asymptomatic and treated brain metastases may participate provided that they are stable for = 2 months. Patients with suspected or confirmed leptomeningeal disease are not eligible even if treated. Patients with glioblastoma multiforme (GBM) are not eligible.
• Clinically significant, active cardiovascular disease such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia, or history of myocardial infarction within 6 months prior to planned start of pemigatinib and afatinib
• Fridericia's corrected QT interval (QTcF) > 480 ms on ECG conducted during Screening, or history of torsades de pointes or personal or family history of prolonged QT syndrome.Correction of suspected drug-induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation.
• Active uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and the sponsor-investigator makes it undesirable for the patient to participate in the trial. Screening for chronic conditions is not required.
• Active hepatitis B virus (HBV) -- Note: Controlled (treated) hepatitis will be allowed if they meet the following criteria: antiviral therapy for HBV must be given for at least 1 month prior to first dose of study drug, and HBV viral load must be less than 2000 IU/ml (104 copies/ml) prior to the first dose of study drug. Those on active HBV therapy with viral loads under 2000 IU/ml (104 copies/ml) should stay on antiviral therapy throughout the study treatment.
• Known human immunodeficiency virus (HIV) and on anti-retroviral therapy for HIV(excluded due to potential drug-drug interactions between anti-retroviral medications and study treatment but HIV itself is not an exclusion).
• Known or suspected active drug or alcohol use
• Concomitant treatment with known strong p-gp inhibitor.
• Use of any potent CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study treatment. -- Note: Moderate CYP3A4 inhibitors are not prohibited
• Pregnancy during the study or within 30 days of the last dose of study intervention. Also excluded are any persons of childbearing potential, including men who are able to father a child, who are unwilling to use a medically acceptable method of contraception during the trial (see below section 3.3). Lactation and breastfeeding during the study or within 30 days of the last dose of study intervention is also not allowed. Female patients must have a negative pregnancy test (B-HCG test in urine or serum) prior to commencing study treatment.
• Unable to swallow pills
• Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the study drug. Patients unable or deemed by the investigator as unlikely to comply with the protocol are also excluded.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Cholangiocarcinoma
• Metastatic Solid Tumor
• Neoplasms

Intervention

Drug:
• Afatinib
Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
• Pemigatinib
Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (3)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Boehringer Ingelheim, Incyte Corporation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, Merritt J, Egan R, Wu MJ, Yin X, Ferrone CR, Deshpande V, Baiev I, Pinto CJ, McLoughlin DE, Walmsley CS, Stone JR, Gordan JD, Zhu AX, Juric D, Goyal L, Benes CH, Bardeesy N. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2022 May 2;12(5):1378-1395. doi: 10.1158/2159-8290.CD-21-1168. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)	All patients in the dose-escalation part who have received = 75% (21 days) of study drug and completed Cycle 1 through Cycle 1 Day 21 or experienced a dose limiting toxicity (DLT)	Through Cycle 1 (21 Days)
Primary	Objective response rate (ORR)	Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in patients with FGFR2-fusion, rearrangement or in-frame deletion positive intrahepatic cholangiocarcinoma. Defined as the proportion of patients achieving Complete response (CR) and partial response(PR) per RECIST v1.1	Baseline, Every 9 weeks during treatment and Off Study up to 1 year
Secondary	Disease Control Rate	Defined as the proportion of patients achieving CR, PR or stable disease (SD) as assessed per RECIST v1.1	Baseline, Every 9 weeks during treatment and Off Study up to 1 year
Secondary	Duration of Response	Defined as the time from first documentation of CR or PR by RECIST v1.1 until the time of first documentation of progressive disease (PD) evaluated using RECIST v1.1 or death due to any cause	Baseline, Every 9 weeks during treatment and Off Study up to 1 year
Secondary	Overall Survival	Defined as the time from date of first dose of study treatment to the date of death by any cause.	Baseline, Every 9 weeks during treatment and Off Study up to 1 year
Secondary	Progression-free Survival	Defined as the time from date of first dose to the earlier date of assessment of progression or death by any cause in the absence of progression, based on the time of first documentation of PD per RECIST v1.1	Baseline, Every 9 weeks during treatment and Off Study up to 1 year
Secondary	Best Overall Response	The best response recorded per RECIST 1.1, from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started).	Baseline, Every 9 weeks during treatment and Off Study up to 1 year
Secondary	Time to response	The time from the date of the first dose to the first objective tumor response (tumor shrinkage of =30%) observed for patients who achieved a CR or PR.	Baseline, Every 9 weeks during treatment and Off Study up to 1 year
Secondary	Treatment Related Adverse Events	Number of Participants with treatment-related adverse events as assessed by CTCAE v5.0 (National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0)	Each visit until 30 days after study discontinuation.
Secondary	Maximum Plasma Concentration [Cmax]) and C trough of pemigatinib and afatinib	To characterize the Pharmacokinetics (PK) properties of the combination of pemigatinib and afatinib	Cycle 1 day 1 and Cycle 1 day 8
Secondary	Molecular correlates of response	Circulating tumor DNA	Through study completion, an average of 6 months.